Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:52 am
Author: Getaka|Social: XLinkedIn

ERIS Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹963.51Overvalued by 26.45%vs CMP ₹1,310.00

P/E (40.9) × ROE (12.9%) × BV (₹227.00) × DY (0.56%)

₹501.50Overvalued by 61.72%vs CMP ₹1,310.00
MoS: -161.2% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹974.9122%Over (-25.6%)
Graham NumberEarnings₹402.3116%Over (-69.3%)
Earnings PowerEarnings₹55.2213%Over (-95.8%)
DCFCash Flow₹220.1313%Over (-83.2%)
Net Asset ValueAssets₹223.147%Over (-83%)
EV/EBITDAEnterprise₹789.599%Over (-39.7%)
Earnings YieldEarnings₹316.907%Over (-75.8%)
ROCE CapitalReturns₹783.209%Over (-40.2%)
Revenue MultipleRevenue₹313.285%Over (-76.1%)
Consensus (9 models)₹501.50100%Overvalued
Key Drivers: Wide model spread (₹55–₹975) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 1.2%

*Investments are subject to market risks

Investment Snapshot

63
ERIS Lifesciences Ltd scores 63/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health78/100 · Strong
ROCE 12.2% GoodROE 12.9% GoodD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money45/100 · Moderate
FII holding down -1.58% (6mo) SellingDII holding up 2.24% MF buyingPromoter holding at 54.9% Stable
Earnings Quality50/100 · Moderate
OPM stable around 35% Steady
Quarterly Momentum68/100 · Strong
Revenue (4Q): +20% YoY GrowingProfit (4Q): +22% YoY Positive
Industry Rank60/100 · Moderate
P/E 40.9 vs industry 53.8 In-lineROCE 12.2% vs industry 16.4% Average3Y sales CAGR: 29% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:52 am

Market Cap 18,152 Cr.
Current Price 1,310
Intrinsic Value₹501.50
High / Low 1,910/1,097
Stock P/E40.9
Book Value 227
Dividend Yield0.56 %
ROCE12.2 %
ROE12.9 %
Face Value 1.00
PEG Ratio34.57

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for ERIS Lifesciences Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Natco Pharma Ltd 17,945 Cr. 1,002 1,060/66011.5 4830.60 %32.8 %28.0 % 2.00
Acutaas Chemicals Ltd 19,093 Cr. 2,332 2,688/93066.5 1730.06 %19.9 %16.0 % 5.00
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
Neuland Laboratories Ltd 16,182 Cr. 12,613 19,748/10,06090.3 1,2630.10 %18.7 %14.8 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of ERIS Lifesciences Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 461423403467505486551720741727705773792
Expenses 309286284297324311402470477477453496504
Operating Profit 151137119170181176148250265250252277288
OPM % 33%32%30%36%36%36%27%35%36%34%36%36%36%
Other Income 52113415254843
Interest 73917161833605957544950
Depreciation 29303541424654768081777169
Profit before tax 1211077611212611677116129116129161173
Tax % 1%6%19%17%3%12%-4%22%25%25%21%22%22%
Net Profit 119100619412210180909687102125134
EPS in Rs 8.857.494.816.989.077.555.226.126.736.156.898.668.82

Last Updated: January 1, 2026, 8:36 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 12:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 5095465977508569821,0741,2121,3471,6852,0092,8943,078
Expenses 4144274254805336377027818581,1461,3321,8761,979
Operating Profit 951181722693223453724314895396771,0181,099
OPM % 19%22%29%36%38%35%35%36%36%32%34%35%36%
Other Income 9732526311292292218-2
Interest 000111232242685231201
Depreciation 51620232636504365117183315287
Profit before tax 98109154270312317331394442405431489608
Tax % 28%18%13%9%6%8%11%10%8%8%8%23%
Net Profit 7189135247295291297355406374397375471
EPS in Rs 5,121.456,489.459,714.1817.9521.3921.1521.8426.1629.8828.1028.8225.8431.69
Dividend Payout % 0%0%63%0%0%0%13%21%20%26%0%28%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)25.35%51.69%82.96%19.43%-1.36%2.06%19.53%14.37%-7.88%6.15%-5.54%
Change in YoY Net Profit Growth (%)0.00%26.33%31.28%-63.53%-20.79%3.42%17.47%-5.16%-22.25%14.03%-11.69%

ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:18%
5 Years:22%
3 Years:29%
TTM:30%
Compounded Profit Growth
10 Years:15%
5 Years:4%
3 Years:-5%
TTM:2%
Stock Price CAGR
10 Years:%
5 Years:29%
3 Years:37%
1 Year:21%
Return on Equity
10 Years:22%
5 Years:18%
3 Years:16%
Last Year:13%

Last Updated: September 5, 2025, 3:40 am

Balance Sheet

Last Updated: February 1, 2026, 12:37 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.140.140.1414141414141414141414
Reserves 1762662995538481,1371,2831,5631,8952,1822,5732,8413,078
Borrowings 110137717607848772,7812,4782,389
Other Liabilities 9491981241701752052022333371,3661,4121,680
Total Liabilities 2713573976921,4081,5021,5021,7852,2263,4106,7346,7447,160
Fixed Assets 7572712327717618758549182,5684,3195,3065,217
CWIP 0000034227222067122
Investments 841671903033653567829452037166768
Other Assets 1121191361572713835446367617832,3791,3041,753
Total Assets 2713573976921,4081,5021,5021,7852,2263,4106,7346,7447,160

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 90901312002352232713753782924861,065
Cash from Investing Activity + -83-92-44-184-590-5123-323-320-975-1,828-78
Cash from Financing Activity + -20-84-24363-221-335-82-456881,380-881
Net Cash Flow 5-24-88-360-3014538105
Free Cash Flow 3877108150210186125350258-550357910
CFO/OP 126%96%97%94%94%85%87%103%94%68%87%114%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow94.00117.00172.00268.00-55.00169.00372.00424.00405.00-338.00675.00-1.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 161616242831534244637758
Inventory Days 166223178195178196148145166136182171
Days Payable 13814292134247200213157166129210170
Cash Conversion Cycle 439710284-4028-123044704859
Working Capital Days 715923-13-1759647550-296-49
ROCE %64%47%53%60%34%26%25%27%25%17%11%12%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 52.86%52.86%54.91%54.90%54.90%54.88%54.87%54.86%54.85%54.83%54.85%54.85%
FIIs 14.86%13.78%13.20%13.13%14.27%14.59%8.01%8.36%8.43%8.39%7.21%6.85%
DIIs 10.02%10.73%14.52%14.55%15.63%16.23%18.64%18.07%18.07%18.18%19.36%20.31%
Public 22.27%22.63%17.37%17.41%15.20%14.30%18.47%18.73%18.64%18.59%18.57%17.97%
No. of Shareholders 45,93144,16942,24546,49651,75344,17646,34653,31450,08752,22559,43854,713

Shareholding Pattern Chart

No. of Shareholders

ERIS Lifesciences Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Small Cap Fund 6,556,651 2.44 901.876,506,6512026-02-23 03:29:500.77%
HDFC Hybrid Equity Fund 2,459,629 1.42 338.32N/AN/AN/A
Franklin India Small Cap Fund 1,866,828 2.01 256.78N/AN/AN/A
DSP Small Cap Fund 1,230,000 1.05 169.19N/AN/AN/A
Franklin India Flexi Cap Fund 1,224,569 0.86 168.44N/AN/AN/A
UTI Flexi Cap Fund 1,173,300 0.69 161.391,217,7512026-01-25 07:18:48-3.65%
HSBC Small Cap Fund 776,897 0.71 106.86N/AN/AN/A
Franklin India Opportunities Fund 771,388 1.28 106.1N/AN/AN/A
UTI Mid Cap Fund 690,000 0.83 94.91643,6782026-01-25 07:18:487.2%
HDFC Large and Mid Cap Fund 675,000 0.33 92.85N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 25.8528.8228.1029.8926.16
Diluted EPS (Rs.) 25.8128.7928.0729.8826.14
Cash EPS (Rs.) 50.6742.6136.1234.6129.32
Book Value[Excl.RevalReserv]/Share (Rs.) 209.57190.11163.30140.35116.10
Book Value[Incl.RevalReserv]/Share (Rs.) 209.57190.11163.30140.35116.10
Revenue From Operations / Share (Rs.) 212.46147.70123.9299.1089.25
PBDIT / Share (Rs.) 76.0351.3640.2937.6032.35
PBIT / Share (Rs.) 52.8737.9431.6832.8429.19
PBT / Share (Rs.) 35.8931.7029.7632.5329.05
Net Profit / Share (Rs.) 27.5029.1927.5129.8526.16
NP After MI And SOA / Share (Rs.) 25.8328.8228.1029.8826.16
PBDIT Margin (%) 35.7834.7732.5137.9336.24
PBIT Margin (%) 24.8825.6825.5633.1332.70
PBT Margin (%) 16.8921.4624.0132.8232.55
Net Profit Margin (%) 12.9419.7622.2030.1229.30
NP After MI And SOA Margin (%) 12.1519.5022.6730.1429.30
Return on Networth / Equity (%) 12.3215.1517.4021.2822.52
Return on Capital Employeed (%) 12.7411.4213.3621.5323.76
Return On Assets (%) 5.005.5610.4217.8719.35
Long Term Debt / Equity (X) 0.600.250.290.020.00
Total Debt / Equity (X) 0.841.060.370.020.00
Asset Turnover Ratio (%) 0.410.370.520.610.67
Current Ratio (X) 0.880.901.733.142.80
Quick Ratio (X) 0.640.831.432.552.23
Inventory Turnover Ratio (X) 11.051.111.261.311.48
Dividend Payout Ratio (NP) (%) 28.430.0026.1520.1021.02
Dividend Payout Ratio (CP) (%) 14.990.0020.0117.3418.75
Earning Retention Ratio (%) 71.570.0073.8579.9078.98
Cash Earning Retention Ratio (%) 85.010.0079.9982.6681.25
Interest Coverage Ratio (X) 4.488.2420.94123.26243.78
Interest Coverage Ratio (Post Tax) (X) 2.625.6815.3098.87198.08
Enterprise Value (Cr.) 21908.9613413.398575.569359.518168.96
EV / Net Operating Revenue (X) 7.576.685.096.956.74
EV / EBITDA (X) 21.1619.2015.6518.3118.60
MarketCap / Net Operating Revenue (X) 6.675.704.626.956.77
Retention Ratios (%) 71.560.0073.8479.8978.97
Price / BV (X) 6.764.423.544.915.21
Price / Net Operating Revenue (X) 6.675.704.626.956.77
EarningsYield 0.010.030.040.040.04

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1697.75 Cr. and Equity Capital is Rs. 13.62 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsShivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054Contact not found
Management
NamePosition Held
Mr. Amit BakshiChairperson & Managing Director
Mr. Krishnakumar VaidyanathanCOO & Executive Director
Mr. Inderjeet Singh NegiExecutive Director
Mr. Kaushal ShahExecutive Director
Mr. Rajeev DalalIndependent Director
Mr. Sujesh VasudevanIndependent Director
Ms. Kalpana UnadkatIndependent Director
Mr. Prashant GuptaIndependent Director

FAQ

What is the intrinsic value of ERIS Lifesciences Ltd and is it undervalued?

As of 09 April 2026, ERIS Lifesciences Ltd's intrinsic value is ₹501.50, which is 61.72% lower than the current market price of ₹1,310.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (12.9 %), book value (₹227), dividend yield (0.56 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd is trading at ₹1,310.00 as of 09 April 2026, with a FY2026-2027 high of ₹1,910 and low of ₹1,097. The stock is currently in the middle of its 52-week range. Market cap stands at ₹18,152 Cr..

How does ERIS Lifesciences Ltd's P/E ratio compare to its industry?

ERIS Lifesciences Ltd has a P/E ratio of 40.9, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is ERIS Lifesciences Ltd financially healthy?

Key indicators for ERIS Lifesciences Ltd: ROCE of 12.2 % is moderate. Dividend yield is 0.56 %.

Is ERIS Lifesciences Ltd profitable and how is the profit trend?

ERIS Lifesciences Ltd reported a net profit of ₹375 Cr in Mar 2025 on revenue of ₹2,894 Cr. Compared to ₹406 Cr in Mar 2022, the net profit shows a declining trend.

Does ERIS Lifesciences Ltd pay dividends?

ERIS Lifesciences Ltd has a dividend yield of 0.56 % at the current price of ₹1,310.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in ERIS Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports